Go Pro
NASDAQ:MBOT

Microbot Medical Q4 2025 Earnings Report

Microbot Medical logo
$1.48 -0.02 (-1.33%)
As of 08/28/2026 04:00 PM Eastern

Microbot Medical EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Microbot Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Microbot Medical Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Thursday, March 26, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Microbot Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Microbot Medical Earnings Headlines

HC Wainwright Cuts Earnings Estimates for Microbot Medical
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.tc pixel
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.

View Microbot Medical Profile